Filings

6 documents · 28 matches

1. KAPA Kairos Pharma, LTD. 10-K 2026-03-31

   Item 1A. Risk Factors

   material weaknesses as efficiently and effectively as possible. We cannot assure you that there will not be future material weaknesses
   13 matches in this document Show context Copy citation

2. KAPA Kairos Pharma, LTD. 10-Q 2026-08-12

   Item 4. Controls and Procedures.

   material weaknesses and control deficiencies. Such material weaknesses and control deficiencies will not be fully remediated until the Company has concluded
   3 matches in this document Show context Copy citation

3. KAPA Kairos Pharma, LTD. 10-Q 2026-05-13

   Item 4. Controls and Procedures.

   material weaknesses and control deficiencies. Such material weaknesses and control deficiencies will not be fully remediated until the Company has concluded
   3 matches in this document Show context Copy citation

4. KAPA Kairos Pharma, LTD. 10-Q 2025-11-14

   Item 4. Controls and Procedures.

   material weaknesses and control deficiencies. Such material weaknesses and control deficiencies will not be fully remediated until the Company has concluded
   3 matches in this document Show context Copy citation

5. KAPA Kairos Pharma, LTD. 10-Q 2025-08-12

   Item 4. Controls and Procedures.

   material weaknesses and control deficiencies. Such material weaknesses and control deficiencies will not be fully remediated until the Company has concluded
   3 matches in this document Show context Copy citation

6. KAPA Kairos Pharma, LTD. 10-Q 2025-05-14

   Item 4. Controls and Procedures.

   material weaknesses and control deficiencies. Such material weaknesses and control deficiencies will not be fully remediated until the Company has concluded
   3 matches in this document Show context Copy citation